Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 – AMBRA” Italian study
Giorgio Mustacchi(University of Trieste), Anna Turletti(Ospedale Martini), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Clara Natoli(Kliniken Essen-Mitte), Filippo Montemurro(Roche (Switzerland)), Monica Giordano(Ospedale Sant'Anna), P. Pronzato(Accademia Nazionale dei Lincei), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Luciano Latini(Ospedale di Macerata), Lorenzo Livi(European Society for Sexual Medicine), Laura Biganzoli(Hospital of Prato), A Michelotti(Presidio Ospedaliero), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Ferdinando Riccardi(Ospedale Antonio Cardarelli), ME Cazzaniga(University of Trieste), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k